David M Peereboom1, Xiaobu Ye2, Tom Mikkelsen3, Glenn J Lesser4, Frank S Lieberman5, H Ian Robins6, Manmeet S Ahluwalia1, Andrew E Sloan7, Stuart A Grossman8. 1. Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, Ohio. 2. Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland. 3. Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan. 4. Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina. 5. Department of Neurology, Hillman Cancer Center of University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 6. Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 7. Department of Neurological Surgery, Seidman Cancer Center, University Hospitals & Case Comprehensive Cancer Center, Cleveland, Ohio. 8. The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Cancer stem-like cells are a major cause of resistance to therapy in patients with glioblastoma (GBM) as well as other cancers. Tumor cells are maintained in a stem-like proliferative state in large part through the Notch signaling pathway. The function of this pathway in turn depends on gamma secretase activity. Inhibition of this enzyme therefore inhibits the Notch pathway and tumor growth as measured by a reduction in the formation of brain tumor neurospheres in murine models. RO4929097 is an oral gamma secretase inhibitor. OBJECTIVE: To estimate the 6-mo progression-free survival rate (PFS6) in patients with progressive GBM and to inhibit by 50% the generation of neurospheres in fresh tissue resected from patients treated with RO4929097. METHODS: In this phase II and pharmacodynamic study, patients with recurrent GBM received RO4929097 in a study of 2 groups. Group A patients had unresectable disease and received drug in a standard phase II design. Group B patients had resectable disease and received drug before and after surgical resection. Endpoints included PFS6 and the inhibition of neurosphere formation in the resected tumor samples. RESULTS: A total of 47 patients received treatment, 7 of whom had tumor resection. The PFS6 was 4%, and the inhibition of neurosphere formation occurred in 1 of 7 patient samples. CONCLUSION: RO4929097 was inactive in recurrent GBM patients and demonstrated minimal inhibition of neurosphere formation in fresh tissue samples.
BACKGROUND: Cancer stem-like cells are a major cause of resistance to therapy in patients with glioblastoma (GBM) as well as other cancers. Tumor cells are maintained in a stem-like proliferative state in large part through the Notch signaling pathway. The function of this pathway in turn depends on gamma secretase activity. Inhibition of this enzyme therefore inhibits the Notch pathway and tumor growth as measured by a reduction in the formation of brain tumor neurospheres in murine models. RO4929097 is an oral gamma secretase inhibitor. OBJECTIVE: To estimate the 6-mo progression-free survival rate (PFS6) in patients with progressive GBM and to inhibit by 50% the generation of neurospheres in fresh tissue resected from patients treated with RO4929097. METHODS: In this phase II and pharmacodynamic study, patients with recurrent GBM received RO4929097 in a study of 2 groups. Group A patients had unresectable disease and received drug in a standard phase II design. Group B patients had resectable disease and received drug before and after surgical resection. Endpoints included PFS6 and the inhibition of neurosphere formation in the resected tumor samples. RESULTS: A total of 47 patients received treatment, 7 of whom had tumor resection. The PFS6 was 4%, and the inhibition of neurosphere formation occurred in 1 of 7 patient samples. CONCLUSION: RO4929097 was inactive in recurrent GBM patients and demonstrated minimal inhibition of neurosphere formation in fresh tissue samples.
Authors: Shideng Bao; Qiulian Wu; Sith Sathornsumetee; Yueling Hao; Zhizhong Li; Anita B Hjelmeland; Qing Shi; Roger E McLendon; Darell D Bigner; Jeremy N Rich Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Benjamin W Purow; Raqeeb M Haque; Martha W Noel; Qin Su; Michael J Burdick; Jeongwu Lee; Tilak Sundaresan; Sandra Pastorino; John K Park; Irina Mikolaenko; Dragan Maric; Charles G Eberhart; Howard A Fine Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300
Authors: Dan R Laks; Michael Masterman-Smith; Koppany Visnyei; Brigitte Angenieux; Nicholas M Orozco; Ian Foran; William H Yong; Harry V Vinters; Linda M Liau; Jorge A Lazareff; Paul S Mischel; Timothy F Cloughesy; Steve Horvath; Harley I Kornblum Journal: Stem Cells Date: 2009-04 Impact factor: 6.277
Authors: Masayuki Kanamori; Tomohiro Kawaguchi; Janice M Nigro; Burt G Feuerstein; Mitchel S Berger; Lucio Miele; Russell O Pieper Journal: J Neurosurg Date: 2007-03 Impact factor: 5.115
Authors: Ran Xu; Fumiko Shimizu; Koos Hovinga; Kathryn Beal; Sasan Karimi; Leif Droms; Kyung K Peck; Philip Gutin; J Bryan Iorgulescu; Thomas Kaley; Lisa DeAngelis; Elena Pentsova; Craig Nolan; Christian Grommes; Timothy Chan; Dylan Bobrow; Adilia Hormigo; Justin R Cross; Nian Wu; Naoko Takebe; Katherine Panageas; Percy Ivy; Jeffrey G Supko; Viviane Tabar; Antonio Omuro Journal: Clin Cancer Res Date: 2016-05-06 Impact factor: 12.531
Authors: Francesca Giordano; Francesca Ida Montalto; Maria Luisa Panno; Sebastiano Andò; Francesca De Amicis Journal: Am J Cancer Res Date: 2021-12-15 Impact factor: 6.166